URL copied to clipboard

Trending News

Hyderabad based pharma stock jumps after it sells 14.38 Acres land in Telangana for ₹115.57 Cr

Hyderabad-based pharma stock sold 14.38 acres in Mekaguda, Telangana, for ₹115.57cr. The sale won’t impact operations and complies with Section 180(1)(a) of the Companies Act, SEBI.
Hyderabad-based pharma stock sells 14.38 acres in Telangana for ₹115.57cr, ensuring no impact on operations.
Hyderabad-based pharma stock sells 14.38 acres in Telangana for ₹115.57cr, ensuring no impact on operations.

Introduction:

Hyderabad-based pharma stock has sold 14.38 acres of land in Mekaguda, Telangana, for ₹115.57 crore, including infrastructure costs. The sale won’t affect business operations, and complies with Section 180(1)(a) of the Companies Act, 2013 and SEBI Listing Regulations, 2015.

Alice Blue Image

Share Price movement of Natco Pharma Ltd:

Natco Pharma Ltd (NATCOPHARM) share price increased slightly by 0.18% to ₹1,353.65. The stock opened at ₹1,368.95, reached a high of ₹1,371.20, and a low of ₹1,350.55. With a previous close of ₹1,351.25, the company’s total market capitalization stands at ₹24,245.21 crore.

Natco Pharma Ltd sells land:

Natco Pharma Ltd has sold 14.38 acres of land, equivalent to 72,358 square yards, located at Mekaguda, Telangana. The immovable property was sold for a total consideration of ₹115.57 crore, including certain infrastructure costs.

The land and building were not associated with any of Natco Pharma Ltd’s ongoing business operations. As a result, the sale will not impact the company’s operational activities, ensuring continuity in its core business functions.

The sale does not constitute an undertaking or substantial undertaking under Section 180(1)(a) of the Companies Act, 2013, and Natco Pharma Ltd has ensured compliance with SEBI Listing Regulations, 2015, during this transaction.

Also Read: Navratna stock jumps 5% after it signs MoU with NBCC for 10 acres of land parcel development

Recent news About Natco Pharma Ltd:

On November 12, 2024, Natco Pharma Ltd reported a consolidated net profit of ₹676 crore for Q2 FY25, an 83% increase from ₹369 crore in the same quarter last year. Revenue rose by 35% to ₹1,371 crore from ₹1,031 crore. 

Ace investor holding of Natco Pharma Ltd:

Ace investor Akash Bhanshali holds 1,800,788 shares of Natco Pharma Ltd, representing a 1.01% stake in the company. At a current price of ₹1,352.75 per share, his holding is valued at ₹243.6 crore, with no change from the previous quarter.

Stock performance of Natco Pharma Ltd for Period of 1 week, 6 months and 1 year:

Natco Pharma Ltd’s stock has shown a decline of 1.71% over the past week. However, over the last six months, it gained 35.4%, and over the past year, it delivered an impressive return of 73.2%, reflecting strong long-term growth.

Also Read: Infra stock jumps 5% after it receives order worth ₹1,704 Cr from Power Grid

Shareholding pattern of Natco Pharma Ltd:

All values in %Sep-24Jun-24Mar-24
Promoters49.6249.7149.71
FII17.5117.4516.14
DII6.767.869.69
Retail & others26.1224.9924.46
Alice Blue Image

About Natco Pharma Ltd:

Natco Pharma Ltd is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of high-quality generic drugs. Known for its expertise in oncology, cardiology, and anti-diabetic products, Natco Pharma is a prominent player in both domestic and international markets.

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.

Loading
Submit the form, and get to know how you scored!!!
Read More News